跳至主要内容
临床试验/NCT04295278
NCT04295278Unknown不适用

An Observational Phase 0 Study to Assess the Performance and Real-world Feasibility of Implementing the MicroKine Dx Biomarker-based Risk Stratification of Critically-ill Pediatric Patients

PreDxion Bio, Inc.0 个研究点目标入组 25 人开始时间: 2021年1月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
25
主要终点
Mortality

研究概览

简要总结

This study will enroll approximately 25 pediatric patients to assess the performance and real-world feasibility of multi-biomarker based prognostic and predictive algorithms to aid in the clinical management of pediatric critically-ill patients.

详细描述

This study will enroll approximately 25 pediatric patients to assess the predictive performance of multi-biomarker based prognostic and predictive algorithms to aid in the clinical management of pediatric critically-ill patients.

All enrolled patients will undergo a series of blood collection procedures during their admission to the pediatric intensive care unit. The levels of inflammatory cytokines, chemokines, and effectors will be assessed and used in multi-biomarker based prognostic and predictive algorithms to determine patients at risk of in-hospital mortality.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
38 Weeks 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Age 38 weeks gestation to 21 years of age
  • Admitted to the PICU within the prior 24 hours
  • Indwelling catheters for obtaining blood
  • Meet ≥2 age-adapted SIRS criteria

排除标准

  • Anticipated pediatric intensive care unit admission <24 hours
  • Primary immunodeficiency
  • Limited resuscitation, no escalation of treatment, do not resuscitate, or other limitations to care
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

结局指标

主要结局

Mortality

时间窗: 28-day

28-day in hospital mortality

次要结局

未报告次要终点

研究者

发起方
PreDxion Bio, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验